Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Art Bechhoefer who wrote (2762)	10/28/1999 7:04:00 PM
From: celeryroot.com	Read Replies (1) \| Respond to of 4676

isis has quite a few alliances with big pharm. Financially they are in much better shape then most bio's at this stage of development. I see no reason to panic.....in fact I was quite pleased with the financials.

To: Art Bechhoefer who wrote (2762)	10/28/1999 7:42:00 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 4676

I wonder what those "total costs" include. How much overhead, how much the development of the base technology vs the individual med, is this for a biotech that will not market, or is this for a big pharma that must support a sales, manufacturing & service organization, provide clinical "bene's" to customers (such as seminars, grants for educational programs) With improved target identification and compound screening using current technology, are past figures really accurate? How many failures are bundled into the cost of an individual med that makes it. Summary - I believe these must be avg costs per approved med, vs the cost to develop, test & get approval for the individual med. IMSCO Scott